Pharmacokinetics, immunogenicity, safety and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).

CONCLUSIONS: Subcutaneous administration of N8-GP is associated with a high incidence of antibodies in PTPs with severe hemophilia A. Further clinical development of s.c. N8-GP has been suspended. PMID: 31618804 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31618804?dopt=Abstract

Source: Thrombosis and Haemostasis - October 15, 2019 Category: Hematology Authors: Klamroth R, Feistritzer C, Friedrich U, Lentz SR, Reichwald K, Zak M, Chowdary P Tags: J Thromb Haemost Source Type: research

More News: Bleeding | Haemophilia | Hematology | Hemophilia | Thrombosis